FDA provided responses to a Type B meeting request and Oragenics conducted a Phase IIa trial in Australia.
1 report, 1 independent
Updated Aug 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA provided responses to a Type B meeting request and Oragenics conducted a Phase IIa trial in Australia.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- NewcelX Ltd. advanced its IND-enabling work for a Phase 1/2a trial and held a successful Type B Pre-IND meeting with the FDA.
- FDA approval enables commercial opportunity involving CBRE Group.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- Nkarta is seeking protocol amendments for its clinical trials under the FDA.
- Atrium and Bristol-Myers Squibb received IND clearance from the FDA and obtained a No Objection Letter for Canadian sites.